相似文献
1
The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.
Vaccine. 2007 Apr 30;25(17):3437-44. doi: 10.1016/j.vaccine.2006.12.045. Epub 2007 Jan 10.
2
Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
Immunology. 2009 Sep;128(1 Suppl):e707-17. doi: 10.1111/j.1365-2567.2009.03068.x. Epub 2009 Feb 9.
3
Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Hum Gene Ther. 2012 Dec;23(12):1301-12. doi: 10.1089/hum.2012.101. Epub 2012 Oct 31.
4
Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Arch Virol. 2018 Mar;163(3):587-597. doi: 10.1007/s00705-017-3647-z. Epub 2017 Nov 17.
5
Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Vaccine. 2009 Sep 25;27(42):5906-12. doi: 10.1016/j.vaccine.2009.07.033. Epub 2009 Aug 3.
6
Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Vaccine. 2006 Jun 12;24(24):5235-44. doi: 10.1016/j.vaccine.2006.03.079. Epub 2006 Apr 18.
7
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
Vaccine. 2009 Jan 14;27(3):431-40. doi: 10.1016/j.vaccine.2008.10.078. Epub 2008 Nov 18.
8
Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
J Virol. 2000 Mar;74(6):2888-94. doi: 10.1128/jvi.74.6.2888-2894.2000.
9
Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
Int J Cancer. 2009 Jul 1;125(1):189-98. doi: 10.1002/ijc.24333.
10
An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Vaccine. 2006 Apr 5;24(15):2880-93. doi: 10.1016/j.vaccine.2005.12.061. Epub 2006 Jan 19.
引用本文的文献
1
Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.
Virol J. 2025 Jan 8;22(1):3. doi: 10.1186/s12985-024-02604-7.
2
HSP70 Family in Cancer: Signaling Mechanisms and Therapeutic Advances.
Biomolecules. 2023 Mar 27;13(4):601. doi: 10.3390/biom13040601.
3
Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.
Front Pharmacol. 2022 Dec 16;13:1065793. doi: 10.3389/fphar.2022.1065793. eCollection 2022.
4
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29. doi: 10.1080/21645515.2015.1136039. Epub 2016 Feb 2.
5
Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors.
PLoS One. 2012;7(12):e52976. doi: 10.1371/journal.pone.0052976. Epub 2012 Dec 31.
6
DNA vaccines for cervical cancer.
Am J Transl Res. 2010 Jan 2;2(1):75-87.
7
Therapeutic HPV DNA vaccines.
Expert Rev Vaccines. 2009 Sep;8(9):1221-35. doi: 10.1586/erv.09.76.
8
Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region.
J Microbiol. 2008 Dec;46(6):728-36. doi: 10.1007/s12275-008-0087-1. Epub 2008 Dec 24.
9
The future of vaccines for cervical cancer.
Gynecol Oncol. 2008 May;109(2 Suppl):S48-56. doi: 10.1016/j.ygyno.2008.01.004.
10
Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.
Clin Vaccine Immunol. 2008 May;15(5):817-24. doi: 10.1128/CVI.00343-07. Epub 2008 Mar 12.
本文引用的文献
1
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant.
J Transl Med. 2006 Oct 23;4:42. doi: 10.1186/1479-5876-4-42.
2
Modifying professional antigen-presenting cells to enhance DNA vaccine potency.
Methods Mol Med. 2006;127:199-220. doi: 10.1385/1-59745-168-1:199.
3
Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Immunol Lett. 2006 Aug 15;106(2):126-34. doi: 10.1016/j.imlet.2006.05.004. Epub 2006 May 22.
4
An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Vaccine. 2006 Apr 5;24(15):2880-93. doi: 10.1016/j.vaccine.2005.12.061. Epub 2006 Jan 19.
5
The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Eur J Gynaecol Oncol. 2005;26(2):129-42.
6
Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.
Vaccine. 2005 Jan 19;23(9):1149-57. doi: 10.1016/j.vaccine.2004.08.027.
7
A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour.
Cancer Immunol Immunother. 2005 Feb;54(2):157-71. doi: 10.1007/s00262-004-0544-6. Epub 2004 Oct 7.
8
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
J Virol. 2004 Aug;78(16):8468-76. doi: 10.1128/JVI.78.16.8468-8476.2004.
9
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.
Vaccine. 2004 Jan 2;22(3-4):520-7. doi: 10.1016/j.vaccine.2003.07.003.
10
Cervical cancer vaccines: recent advances in HPV research.
Viral Immunol. 2003;16(2):111-21. doi: 10.1089/088282403322017866.
Zotero 插件